Subscribe To
NBTX / Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major' drug maker on development of cancer treatment
Content Topics
Nanobiotix
Stock
More
Than
Triples
After
Biotech
Enters
Triples
Negotiations
major
Development
Cancer
Treatment
NBTX
NBTX News
By Seeking Alpha
September 27, 2023
Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q2 2023 Earnings Conference Call September 27, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - more_horizontal
By Seeking Alpha
August 24, 2023
Nanobiotix: At A Crucial Juncture For Data
Nanobiotix is an oncology-focused biotech aiming for its first drug approval, with a tripled value since the beginning of 2023. Their flagship molecul more_horizontal
By Proactive Investors
May 5, 2023
Nanobiotix stock skyrockets on final negotiations with ‘major' drug maker for its cancer treatment
Nanobiotix SA (EPA:NANO) shares soared 250% to $7.11, on volume of more than 29 million shares, Friday after the France-based clinical biotechnology c more_horizontal
By Market Watch
May 5, 2023
Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major' drug maker on development of cancer treatment
The U.S.-listed shares of Nanobiotix S.A. NBTX blasted 221.7% higher on massive volume Friday, to pace all gainers trading on major U.S. exchanges, af more_horizontal
By InvestorPlace
May 5, 2023
Why is Nanobiotix (NBTX) Stock Up 107% Today?
Nanobiotix (NASDAQ: NBTX ) stock is taking off on Friday after the company revealed details about ongoing contract negotiations for NBTXR3. NBTXR3 is more_horizontal
By Seeking Alpha
March 31, 2022
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call Transcript
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call Transcript more_horizontal